Cargando…
Oncogenic KRAS G12D mutation promotes dimerization through a second, phosphatidylserine–dependent interface: a model for KRAS oligomerization
KRAS forms transient dimers and higher-order multimers (nanoclusters) on the plasma membrane, which drive MAPK signaling and cell proliferation. KRAS is a frequently mutated oncogene, and while it is well known that the most prevalent mutation, G12D, impairs GTP hydrolysis, thereby increasing KRAS a...
Autores principales: | Lee, Ki-Young, Enomoto, Masahiro, Gebregiworgis, Teklab, Gasmi-Seabrook, Geneviève M. C., Ikura, Mitsuhiko, Marshall, Christopher B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494122/ https://www.ncbi.nlm.nih.gov/pubmed/34703570 http://dx.doi.org/10.1039/d1sc03484g |
Ejemplares similares
-
Targeting plasma membrane phosphatidylserine content to inhibit oncogenic KRAS function
por: Kattan, Walaa E, et al.
Publicado: (2019) -
Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation
por: Kano, Yoshihito, et al.
Publicado: (2019) -
The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors
por: Gebregiworgis, Teklab, et al.
Publicado: (2021) -
Oncogenic KRAS signalling in pancreatic cancer
por: Eser, S, et al.
Publicado: (2014) -
Oncogenic KRAS: Signaling and Drug Resistance
por: Kim, Hyeon Jin, et al.
Publicado: (2021)